Dragon Pharma, Europe
Cut Mix 150
Injection · 150 mg/ml · 10 ml
$67.00
Compound ID
Drostanolone Enanthate / Trenbolone Enanthate / Testosterone Enanthate
Dosage
500–700 mg/week
Concentration
150 mg/mL
Components
Masteron E + Tren E + Test E
Half-life
16 days
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Cut Mix 150mg/mL — Precision-Engineered Injectable Blend for Advanced Physique Refinement & Competition Conditioning
Dragon Pharma Cut Mix 150mg/mL represents a sophisticated, multi-ester injectable formulation engineered specifically for the advanced physique athlete navigating aggressive cutting or recomposition phases. This synergistic combination of Trenbolone Acetate, Drostanolone Propionate, and Testosterone Propionate delivers a tripartite pharmacological approach to body composition optimization: potent lipolytic and nutrient-partitioning drive from Trenbolone, exceptional muscular dryness and definition from Drostanolone, and foundational anabolic support with manageable estrogenic liability from Testosterone.
The short-ester architecture of all three components ensures rapid systemic onset, precise dose titration, and swift clearance—making this blend ideal for athletes who require immediate visual changes and flexible protocol adjustments during the final weeks before competition or photo-ready conditioning. Dragon Pharma's sterile, pharmaceutical-grade manufacturing and independent batch verification ensure that each 10mL vial delivers exactly the stated 150mg per milliliter concentration, providing the dosing consistency essential for advanced cutting protocols.
What is Dragon Pharma Cut Mix 150?
Cut Mix 150 is a sterile oil-based injectable solution containing three distinct short-ester anabolic-androgenic steroids in a precisely calibrated 150mg per milliliter blend.
Each milliliter delivers Trenbolone Acetate, Drostanolone Propionate, and Testosterone Propionate in a synergistic ratio designed to maximize lipolysis, muscular hardness, and lean tissue preservation while minimizing subcutaneous fluid retention. Trenbolone Acetate contributes its legendary nutrient-partitioning efficiency and metabolic rate elevation; Drostanolone Propionate provides the DHT-derived hardness, anti-estrogenic activity, and muscular density prized in pre-contest preparation; and Testosterone Propionate supplies the essential anabolic foundation that maintains physiological androgen levels and supports libido, mood, and training intensity.
All three esters—acetate and propionate—share similarly brief active half-lives of approximately 48–72 hours, necessitating frequent administration but allowing for rapid protocol adjustments and streamlined post-cycle transition. Dragon Pharma's 10mL multi-dose vials are manufactured under strict aseptic conditions with pharmaceutical-grade carrier oils and verified active ingredient concentrations.
Key Benefits / Effects
- Accelerated Lipolytic Metabolism: Trenbolone's potent nutrient-partitioning effects redirect dietary calories toward muscle glycogen and protein synthesis rather than adipose storage, supporting visible fat reduction even at moderate caloric deficits.
- Exceptional Muscular Hardness: Drostanolone's DHT-derived anti-estrogenic properties and strong androgen receptor binding produce a dry, grainy, and striated aesthetic with pronounced muscle separation and visual density.
- Lean Tissue Preservation: The combined anabolic signaling of all three compounds creates a powerfully anti-catabolic environment that protects contractile muscle mass during aggressive hypocaloric cutting phases.
- Enhanced Venous Prominence: Reduced subcutaneous water retention combined with increased hematocrit and vascular tone produces dramatic vein visibility across deltoids, arms, and quadriceps as body fat decreases.
- Sustained Training Output: Despite energy restriction, the androgenic drive from Trenbolone and Testosterone helps maintain strength levels, training aggression, and progressive overload capacity throughout the cutting cycle.
- Rapid Onset & Clearance: The short ester profile enables noticeable physiological changes within the first 7–10 days and permits swift hormonal normalization following cycle cessation, streamlining PCT timing.
How Dragon Pharma Cut Mix 150 Works
The blend operates through three convergent pharmacological pathways that collectively create an optimal cutting environment. Trenbolone Acetate binds with ultra-high affinity to androgen receptors in skeletal muscle and adipose tissue, upregulating lipolytic enzyme activity while simultaneously enhancing insulin sensitivity and nutrient uptake in myocytes.
This dual action increases metabolic rate and directs substrate utilization away from fat storage. Drostanolone Propionate, as a 5-alpha-reduced DHT derivative, exhibits strong androgenic activity with inherent anti-estrogenic properties—it competes with estradiol for receptor binding in breast and adipose tissue while promoting muscular density through enhanced myofibrillar contractile quality. Testosterone Propionate serves as the hormonal foundation, maintaining physiological androgen levels that support mood, libido, joint health, and baseline anabolism.
The propionate and acetate esters undergo rapid enzymatic hydrolysis in plasma, releasing the free steroid hormones within 24–48 hours of injection. This creates a pulsatile yet stable anabolic milieu that maximizes lipolysis and hardness while avoiding the fluid retention and extended suppression associated with longer esters like Enanthate or Decanoate.
Usage Information
Dragon Pharma Cut Mix 150 is supplied as a 150mg per milliliter oil-based injectable solution in 10mL multi-dose vials, designed exclusively for intramuscular administration by experienced male athletes. Due to the short ester profile of all three components, injections must be administered every other day (EOD) to maintain stable plasma concentrations and prevent pronounced hormonal fluctuation.
Beginner and intermediate users typically employ 0.5–1.0mL per injection, yielding approximately 225–450mg weekly. Advanced practitioners may escalate to 1.0–1.5mL EOD, producing weekly totals of 450–675mg, though the extreme potency of the Trenbolone component demands conservative titration. Standard cycle duration ranges from 8–10 weeks, with some advanced users extending to 12 weeks under comprehensive health monitoring. The blend is almost exclusively deployed during cutting or recomposition phases and stacks effectively with non-aromatizing orals such as Stanozolol or Oxandrolone, as well as thermogenic agents like Clenbuterol.
Aromatase inhibitor management is typically required for the Testosterone Propionate component, while prolactin monitoring may be prudent given Trenbolone's progestogenic activity. Intramuscular injections should rotate between gluteal, deltoid, and vastus lateralis sites to minimize localized tissue irritation.
Quality & Manufacturing
Dragon Pharma maintains rigorous pharmaceutical manufacturing standards across all injectable production lines, with each Cut Mix 150 batch subjected to independent third-party laboratory analysis to verify sterility, active ingredient concentration, endotoxin levels, and heavy metal absence. The precise blending of three distinct short-ester compounds in a single carrier oil requires sophisticated compounding technology to ensure uniform distribution and prevent phase separation or concentration gradients.
Dragon Pharma's analytical verification confirms that each vial delivers exactly the stated 150mg per milliliter total concentration, with individual component ratios maintained within tight pharmaceutical tolerances. In the multi-compound injectable marketplace, where blending errors, underdosing, and bacterial contamination are significant risks, this commitment to manufacturing precision and batch transparency provides advanced users with the confidence to program complex cutting protocols without the uncertainty of variable potency or compromised sterility.
Possible Side Effects / Safety Information
- Androgenic Dermatological Effects: The combined androgenic load from Trenbolone, Drostanolone, and Testosterone can increase sebaceous activity causing acne and oily skin, accelerate male pattern baldness in predisposed individuals, and stimulate body hair growth.
- Cardiovascular Dyslipidemia: Trenbolone and Drostanolone can significantly depress HDL cholesterol while elevating LDL cholesterol and triglycerides, necessitating omega-3 supplementation, dietary fiber, and regular cardiovascular monitoring.
- Profound HPTA Suppression: All three components suppress endogenous testosterone production, requiring a structured Post-Cycle Therapy protocol and potentially HCG during the cycle to maintain testicular function.
- Trenbolone-Specific Effects: Users may experience night sweats, insomnia, increased body temperature, anxiety or "Tren cough" following injection, and heightened aggression or irritability.
- Progestogenic Activity: Trenbolone's affinity for progesterone receptors can contribute to gynecomastia risk in sensitive individuals, particularly when combined with aromatizing testosterone; prolactin management may be necessary.
- Injection Site Reactions: Frequent EOD injections increase the likelihood of post-injection pain, localized swelling, or scar tissue accumulation without diligent site rotation and proper technique.
- Estrogenic Management: The Testosterone Propionate component aromatizes to estradiol, requiring aromatase inhibitor availability to control water retention, gynecomastia, and blood pressure elevation.
Why Choose Dragon Pharma Cut Mix 150?
Advanced cutting protocols demand compounds that deliver precise, predictable, and synergistic pharmacological effects without the logistical complexity of managing three separate vials, injection schedules, and carrier oils. Dragon Pharma's pre-formulated Cut Mix 150 eliminates these variables by combining Trenbolone, Drostanolone, and Testosterone in a single, verified, sterile solution with matched ester kinetics.
This integration ensures that all three agents peak and clear simultaneously, preventing the hormonal asynchrony that can occur when stacking disparate esters. For the experienced athlete who understands that competition conditioning requires not just fat loss but the preservation of hard-earned mass, vascular clarity, and muscular density, this blend offers a streamlined, pharmaceutical-grade platform. Dragon Pharma's batch testing and sterility assurance transform what could be a complex, risky protocol into a calculated, efficient pathway to stage-ready or photo-shoot conditioning.
Lab Report
Lab Report: 148.4 mg
25 Mar 2026
150 mg of label claim
| Analysis Date | 2026-03-25 |
| Lot / Batch ID | #CA2Q17 |
| Measured Potency | 148.4 mg |
| Quality Assessment | Potency verified, purity passed, heavy metals passed. |
| Current Production Batch | Latest Batch |
Verify this result with your scratch-off code at the DPStore register.
Lost some good weight on this and my strength was through the roof. Got my 6 pack in about 5 weeks! Great product!
Took 1 ml eod for eight weeks added 1/2 ml eod of test prop to cycle love it energy and libido through the roof also made me look great
Cut Mix 150 is the real deal real deal Holyfield. Two weeks into a 4 week cycle and I can't believe how fast this is working. Just warm is up first in some hot water.
Product FAQ
Questions, answered
The pre-blended formulation ensures pharmacokinetic synchronization—all three short esters peak and decline in unison, creating a stable, predictable anabolic environment. When purchased and injected separately, users risk mismatched ester clearance rates, inconsistent carrier oil volumes, and dosing calculation errors. The blend also reduces injection volume and frequency, as a single 1mL EOD injection replaces multiple separate administrations. Dragon Pharma's verified concentration guarantees exact component ratios, whereas self-mixing introduces compounding uncertainty.
Short esters like Propionate and Acetate offer several strategic advantages during cutting. They produce rapid visible changes within days rather than weeks, allowing athletes to time peak conditioning precisely for competitions or photo shoots. They also clear the system quickly, enabling faster transition into Post-Cycle Therapy and reducing the duration of metabolic suppression. Additionally, short esters typically produce less subcutaneous fluid retention than longer esters, supporting the dry, defined aesthetic central to cutting objectives. The trade-off is more frequent injections, which most advanced users accept for the precision and control gained.
For maximum conditioning, stack the blend with Stanozolol at 50mg daily for the final 6 weeks to amplify dryness and vascularity, or Oxandrolone at 50mg daily for a slightly milder but highly effective hardening effect. Thermogenic support from Clenbuterol in a two-weeks-on, two-weeks-off protocol can accelerate fat loss. Aromatase inhibitor management with Exemestane or Anastrozole controls estrogen from the Testosterone Propionate component. Some advanced users add Methenolone Enanthate at 400mg weekly for additional lean tissue preservation without increasing androgenic burden.
Due to the short ester profile, most users report subjective improvements in training aggression, muscle hardness, and vascularity within the first 7–10 days. Visible fat loss and definition changes typically consolidate by week 3, with maximal dryness, separation, and vein prominence appearing between weeks 6 and 10. The rapid onset allows athletes to make real-time dietary and dosing adjustments based on mirror feedback, a significant advantage over slower-acting cutting compounds.
Gynecomastia risk arises from two pathways: aromatization of Testosterone Propionate to estradiol, and progestogenic activity from Trenbolone Acetate. Management requires a dual approach—aromatase inhibitors such as Exemestane (12.5–25mg EOD) or Anastrozole (0.5mg EOD) control estrogen from the testosterone component, while dopamine agonists like Cabergoline (0.25mg twice weekly) may be necessary for users sensitive to Trenbolone's progestogenic effects. Nipple sensitivity monitoring should begin in week 2, with immediate pharmacological intervention upon early symptoms.
Every-other-day administration is the standard minimum for this blend. A Monday/Wednesday/Friday/Sunday rotation provides consistent plasma levels while allowing 48 hours between injections for tissue recovery. Some users prefer daily injections at half the EOD volume to further smooth hormonal fluctuations and reduce individual injection volume, though this increases injection frequency. Site rotation among gluteal, deltoid, and vastus lateralis muscles is essential to prevent lipohypertrophy or scar tissue accumulation over 8–12 week cycles.
The Trenbolone and Drostanolone components can produce significant unfavorable shifts in lipid profiles, including HDL depression and LDL elevation. Blood pressure may increase due to androgenic vasoconstriction and hematocrit elevation. Protective measures include high-dose omega-3 fatty acid supplementation (3–6g EPA/DHA daily), regular low-intensity cardiovascular exercise, dietary fiber intake, and abstinence from alcohol. Pre-cycle, mid-cycle (week 6), and post-cycle lipid panels are strongly recommended, particularly for athletes with pre-existing cardiovascular risk factors.
Because all three esters are short-acting, PCT can begin approximately 3–5 days after the final injection. A comprehensive protocol includes Clomiphene Citrate at 50/50/25/25mg and Tamoxifen Citrate at 40/20/20/20mg over four weeks. For 10–12 week cycles, extending PCT to 6 weeks or combining both SERMs may accelerate recovery. HCG at 500IU every other day during the final 2 weeks of the cycle can prime testicular responsiveness before SERM initiation. Blood work confirming recovered LH, FSH, and total testosterone should precede any subsequent cycle.
No. The combined androgenic potency of Trenbolone, Drostanolone, and Testosterone creates an exceptionally high virilization risk that is categorically unsuitable for female physiology. Even at micro-doses, the rapid onset of voice deepening, clitoral enlargement, facial hair growth, and menstrual disruption would be nearly certain. Women seeking cutting support should explore significantly milder compounds such as Oxandrolone or non-hormonal alternatives with established female safety profiles.
Tren cough—a sudden, intense coughing fit immediately following injection—is thought to result from minute quantities of Trenbolone entering the bloodstream and irritating pulmonary capillaries. While generally benign and self-limiting within minutes, it can be alarming. Mitigation strategies include injecting slowly over 60–90 seconds, ensuring the needle has not entered a blood vessel by aspirating before plunging, keeping injection volume moderate (1mL or less per site), and warming the oil to body temperature before administration. If cough occurs, remain calm, sit upright, and allow the episode to pass naturally.
Unlike C17-alpha alkylated oral steroids, injectable Trenbolone, Drostanolone, and Testosterone do not directly stress hepatic enzyme systems. However, Trenbolone can elevate liver enzymes in some individuals through mechanisms unrelated to C17-aa toxicity. Standard liver support with N-acetylcysteine (NAC) at 600–1200mg daily is a reasonable precaution, particularly when stacking with oral cutting agents like Stanozolol or Oxandrolone. Pre-cycle and mid-cycle liver panels provide additional safety oversight.
Comprehensive panels should include total and free testosterone, estradiol, prolactin, complete blood count with hematocrit, comprehensive metabolic panel with liver enzymes (ALT, AST, ALP, GGT), and a full lipid profile (total cholesterol, HDL, LDL, triglycerides). Baseline testing before cycle initiation establishes reference ranges. Mid-cycle assessment at week 5–6 identifies emerging dyslipidemia, hematocrit elevation, or prolactin issues. Post-cycle testing at weeks 2 and 4 after the final injection confirms hormonal recovery trajectory. Blood pressure should be monitored weekly throughout the cycle.
While technically capable of supporting lean mass accretion due to the potent anabolic signaling from all three components, the blend is specifically formulated and dosed for cutting optimization. The Drostanolone component's anti-estrogenic and hardening effects are wasted during caloric surplus bulking, and the short esters require inconvenient frequent injections for longer mass phases where Enanthate or Decanoate esters would be more practical. For pure bulking, a Testosterone/Nandrolone base with a longer-estered Trenbolone is generally more efficient. Cut Mix 150 excels in its intended role: preserving mass while maximizing definition.
